JP2021036909A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021036909A5 JP2021036909A5 JP2020196110A JP2020196110A JP2021036909A5 JP 2021036909 A5 JP2021036909 A5 JP 2021036909A5 JP 2020196110 A JP2020196110 A JP 2020196110A JP 2020196110 A JP2020196110 A JP 2020196110A JP 2021036909 A5 JP2021036909 A5 JP 2021036909A5
- Authority
- JP
- Japan
- Prior art keywords
- sample
- immunogenic
- quantifying
- vaccine
- influenza vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101710043164 Segment-4 Proteins 0.000 claims 15
- 101700038759 VP1 Proteins 0.000 claims 15
- 101700005460 hemA Proteins 0.000 claims 15
- 239000000185 hemagglutinin Substances 0.000 claims 15
- 229960005486 vaccines Drugs 0.000 claims 11
- 208000006572 Human Influenza Diseases 0.000 claims 10
- 206010022000 Influenza Diseases 0.000 claims 10
- 230000002163 immunogen Effects 0.000 claims 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 6
- 108091005771 Peptidases Proteins 0.000 claims 4
- 239000004365 Protease Substances 0.000 claims 4
- 102000033147 ERVK-25 Human genes 0.000 claims 3
- 230000000240 adjuvant Effects 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 235000018102 proteins Nutrition 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 230000017854 proteolysis Effects 0.000 claims 3
- 230000002797 proteolythic Effects 0.000 claims 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 2
- 238000004587 chromatography analysis Methods 0.000 claims 2
- 238000004128 high performance liquid chromatography Methods 0.000 claims 2
- 238000004949 mass spectrometry Methods 0.000 claims 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- 238000004007 reversed phase HPLC Methods 0.000 claims 2
- 102000035336 Aspartic proteases Human genes 0.000 claims 1
- 108091005540 Aspartic proteases Proteins 0.000 claims 1
- 102000005927 Cysteine Proteases Human genes 0.000 claims 1
- 108010005843 Cysteine Proteases Proteins 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 102000005741 Metalloproteases Human genes 0.000 claims 1
- 108010006035 Metalloproteases Proteins 0.000 claims 1
- 102000035443 Peptidases Human genes 0.000 claims 1
- 102000012479 Serine Proteases Human genes 0.000 claims 1
- 108010022999 Serine Proteases Proteins 0.000 claims 1
- 210000002845 Virion Anatomy 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000002244 precipitate Substances 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
Claims (19)
- 試料中の免疫原性インフルエンザヘマグルチニン(HA)を定量するための方法であって、
a)前記試料を、生物学的タンパク質分解に供するステップであって、ここで、不活性HAが消化され、前記免疫原性HAが消化されないままであり、前記生物学的タンパク質分解が、プロテアーゼによるタンパク質分解を含み、さらに、前記プロテアーゼが、セリンプロテアーゼ、トレオニンプロテアーゼ、システインプロテアーゼ、アスパラギン酸プロテアーゼ、グルタミン酸プロテアーゼ、またはメタロプロテアーゼであるステップと;
b)前記試料中の前記免疫原性HAを、他の成分から分離するステップと;
c)前記試料中の前記免疫原性HAを定量するステップと
を含む方法。 - 前記免疫原性HAを分離するステップが、タンパク質沈殿を含む、請求項1に記載の方法。
- 前記タンパク質沈殿が、有機溶媒を添加するステップを含む、請求項2に記載の方法。
- 前記有機溶媒が、アセトン、エタノール、またはメタノールである、請求項3に記載の方法。
- 前記沈殿したタンパク質を、アルコールで洗浄するステップを含む、請求項2から4のいずれか一項に記載の方法。
- 前記アルコールがエタノールである、請求項5に記載の方法。
- 前記免疫原性HAを定量化するステップが、クロマトグラフィー法、二次元ゲル電気泳動または質量分析法を含む、請求項1から6のいずれかに記載の方法。
- 前記質量分析法が液体クロマトグラフィー−質量分析(LC−MS)である、請求項7に記載の方法。
- 前記クロマトグラフィー法が高速液体クロマトグラフィー(HPLC)である、請求項7に記載の方法。
- 前記HPLCが逆相HPLC(RP−HPLC)である、請求項9に記載の方法。
- 前記免疫原性HAを定量化するステップがSRIDの使用を含む、請求項1から6のいずれか一項に記載の方法。
- 前記試料が融合前HAおよび融合後HAを含む、請求項1から11のいずれかに記載の方法。
- 前記試料が、全ビリオンインフルエンザワクチン、スプリットインフルエンザワクチン、サブユニットインフルエンザワクチン、および組換えインフルエンザワクチンからなる群から選択される、請求項1から12のいずれかに記載の方法。
- 前記試料が、アジュバントを含む、請求項13に記載の方法。
- 前記アジュバントが、水中油エマルジョンアジュバントである、請求項14に記載の方法。
- 前記試料がインフルエンザワクチンバルク調製物またはインフルエンザワクチンから得られる、請求項1から15のいずれかに記載の方法。
- 前記バルクまたは前記ワクチンが多価である、請求項16に記載の方法。
- インフルエンザワクチンを製造するための方法であって、
a)インフルエンザHAを含むバルク調製物に由来する試料を提供するステップと、
b)免疫原性HAの量を、請求項1から17のいずれかに記載の方法に従い定量するステップと、
c)単位剤形を、前記バルク調製物から、前記試料中の免疫原性HAの量に従いパッケージングするステップと
を含む方法。 - インフルエンザワクチンを調製するための方法であって、
a)請求項1から17のいずれか一項に記載の方法により、バルクワクチン中のHAの量を定量するステップと;
b)ワクチンを前記バルクから調製するステップと
を含む方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021215382A JP7232893B2 (ja) | 2015-07-07 | 2021-12-29 | インフルエンザ効力アッセイ |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15175765 | 2015-07-07 | ||
EP15175765.5 | 2015-07-07 | ||
EP16152829.4 | 2016-01-26 | ||
EP16152829 | 2016-01-26 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017567171A Division JP6830070B2 (ja) | 2015-07-07 | 2016-07-07 | インフルエンザ効力アッセイ |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021215382A Division JP7232893B2 (ja) | 2015-07-07 | 2021-12-29 | インフルエンザ効力アッセイ |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021036909A JP2021036909A (ja) | 2021-03-11 |
JP2021036909A5 true JP2021036909A5 (ja) | 2021-09-30 |
JP7069281B2 JP7069281B2 (ja) | 2022-05-17 |
Family
ID=56409603
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017567171A Active JP6830070B2 (ja) | 2015-07-07 | 2016-07-07 | インフルエンザ効力アッセイ |
JP2020196110A Active JP7069281B2 (ja) | 2015-07-07 | 2020-11-26 | インフルエンザ効力アッセイ |
JP2021215382A Active JP7232893B2 (ja) | 2015-07-07 | 2021-12-29 | インフルエンザ効力アッセイ |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017567171A Active JP6830070B2 (ja) | 2015-07-07 | 2016-07-07 | インフルエンザ効力アッセイ |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021215382A Active JP7232893B2 (ja) | 2015-07-07 | 2021-12-29 | インフルエンザ効力アッセイ |
Country Status (11)
Country | Link |
---|---|
US (2) | US10416171B2 (ja) |
EP (2) | EP3320343B1 (ja) |
JP (3) | JP6830070B2 (ja) |
KR (2) | KR102576962B1 (ja) |
CN (2) | CN108027371B (ja) |
AU (1) | AU2016290603B2 (ja) |
BR (1) | BR112018000296A2 (ja) |
CA (1) | CA2990745A1 (ja) |
HK (1) | HK1254342A1 (ja) |
HU (2) | HUE051783T2 (ja) |
WO (1) | WO2017005880A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170258883A1 (en) * | 2005-10-03 | 2017-09-14 | Yong Qian | Protease-engineered Cancer Cell Spheres as an Immunotherapy to Treat Cancer and non-Cancer Diseases |
EP3781946A4 (en) | 2018-04-18 | 2022-01-19 | BioMadison, Inc. | METHODS FOR DETERMINING VACCINE ACTIVITY |
CA3125040A1 (en) * | 2019-01-25 | 2020-07-30 | Regeneron Pharmaceuticals, Inc. | Online chromatography and electrospray ionization mass spectrometer |
JP7514789B2 (ja) | 2021-04-08 | 2024-07-11 | 日本電子株式会社 | ウイルス由来タンパク質検出方法、マススペクトル処理装置及び質量分析システム |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
US5762939A (en) | 1993-09-13 | 1998-06-09 | Mg-Pmc, Llc | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus |
AU5543294A (en) | 1993-10-29 | 1995-05-22 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
DE19612967A1 (de) | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
CA2274587A1 (en) | 1996-12-10 | 1998-06-18 | Genetrace Systems Inc. | Releasable nonvolatile mass-label molecules |
TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
AU7126998A (en) | 1997-04-16 | 1998-11-11 | Connaught Laboratories Inc. | Anti-influenza compositions supplemented with neuraminidase |
US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
WO1999006565A2 (en) * | 1997-07-31 | 1999-02-11 | Ice Biotech Inc. | Antifreeze proteins, dna and expression systems |
GB9718921D0 (en) | 1997-09-05 | 1997-11-12 | Brax Genomics Ltd | Catalytically generated mass labels |
ATE375803T1 (de) | 1998-05-07 | 2007-11-15 | Corixa Corp | Adjuvanszusammensetzung und methoden zu deren verwendng |
US6544785B1 (en) | 1998-09-14 | 2003-04-08 | Mount Sinai School Of Medicine Of New York University | Helper-free rescue of recombinant negative strand RNA viruses |
PT1820853E (pt) | 1999-04-06 | 2012-01-03 | Wisconsin Alumni Res Found | Vírus recombinante da gripe para vacinas e terapia genética |
ATE353370T1 (de) | 1999-07-14 | 2007-02-15 | Sinai School Medicine | In vitro-rekonstitution von segmentierten, negativstrang-rna-viren |
BR0014281A (pt) | 1999-09-24 | 2002-05-21 | Smithkline Beecham Biolog | Vacina contra vìrus de gripe intranasal |
GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
EP1103610A1 (en) * | 1999-11-26 | 2001-05-30 | Introgene B.V. | Production of vaccines from immortalised mammalian cell lines |
EP1260581B1 (en) | 2000-03-03 | 2010-07-07 | Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute | Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell |
KR100848719B1 (ko) | 2000-04-28 | 2008-07-25 | 세인트 쥬드 칠드런즈 리써치 호스피탈 | 감염성 인플루엔자 바이러스 생성용 dna 트랜스펙션시스템 |
FR2808803B1 (fr) | 2000-05-11 | 2004-12-10 | Agronomique Inst Nat Rech | Cellules es modifiees et gene specifique de cellules es |
GB0024089D0 (en) | 2000-10-02 | 2000-11-15 | Smithkline Beecham Biolog | Novel compounds |
AR032575A1 (es) | 2001-02-23 | 2003-11-12 | Smithkline Beecham Biolog | Uso de una preparacion antigenica de gripe para la fabricacion de una vacuna intradermica de la gripe y estuche farmaceutico que comprende dicha vacuna |
DE60239594D1 (de) | 2001-02-23 | 2011-05-12 | Glaxosmithkline Biolog Sa | Influenza vakzinzusammensetzungen zur intradermaler verabreichung |
TWI228420B (en) | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
DE10144903A1 (de) | 2001-09-12 | 2003-03-27 | Chiron Behring Gmbh & Co | Vermehrung von Viren in Zellkultur |
DE10144906B4 (de) | 2001-09-12 | 2013-11-28 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur großtechnischen Herstellung von Impfstoffen |
FR2832423B1 (fr) | 2001-11-22 | 2004-10-08 | Vivalis | Systeme d'expression de proteines exogenes dans un systeme aviaire |
FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
ES2383259T3 (es) * | 2003-10-15 | 2012-06-19 | Sekisui Medical Co., Ltd. | Método para analizar selectivamente multímeros de adiponectina |
EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
AU2005223371B2 (en) * | 2004-03-17 | 2011-06-09 | Crucell Holland B.V. | Novel assay for the separation and quantification of hemagglutinin antigens |
KR20090051129A (ko) | 2004-04-05 | 2009-05-20 | 화이자 프로덕츠 인코포레이티드 | 미세유체화된 수중유 유화액 및 백신 조성물 |
WO2005113756A1 (en) | 2004-05-14 | 2005-12-01 | Glaxosmithkline Biologicals S.A. | Method |
JP2007537760A (ja) | 2004-05-20 | 2007-12-27 | アイディー バイオメディカル コーポレイション | インフルエンザワクチンを製造するためのプロセス |
RS51721B (en) | 2004-09-09 | 2011-10-31 | Novartis Vaccines And Diagnostics Gmbh. | Reduction of potential iatrogenic risks associated with influenza vaccines |
AU2005322353B2 (en) | 2004-12-23 | 2011-09-01 | Medimmune, Llc | Non-tumorigenic MDCK cell line for propagating viruses |
RU2435855C2 (ru) | 2004-12-24 | 2011-12-10 | Солвей Байолоджикалз Б.В. | Способ продуцирования репликативной частицы вируса гриппа, композиция клеток (варианты), композиция клеточной культуры и ее применение |
FR2884255B1 (fr) | 2005-04-11 | 2010-11-05 | Vivalis | Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe |
US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
AU2006310171B2 (en) | 2005-11-01 | 2011-02-17 | Seqirus UK Limited | Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment |
FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
PL1976559T6 (pl) * | 2006-01-27 | 2020-08-10 | Novartis Influenza Vaccines Marburg Gmbh | Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy |
PT2086582E (pt) | 2006-10-12 | 2013-01-25 | Glaxosmithkline Biolog Sa | Vacina compreendendo uma emulsão adjuvante óleo em água |
EP2045323A1 (en) | 2007-10-05 | 2009-04-08 | Avir Green Hills Biotechnology Research Development Trade Ag | Linear expression constructs for production of influenza virus particles |
EP2232258A4 (en) | 2007-12-05 | 2011-01-05 | Govt Of The U S A As Represented By The Secretary Of The Dept Of Health & Human Services | IMPROVED VIRAL PROTEIN QUANTIFICATION AND VACCINE QUALITY CONTROL THEREWITH |
JP2012507272A (ja) | 2008-11-05 | 2012-03-29 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 新規な方法 |
JP2010112788A (ja) * | 2008-11-05 | 2010-05-20 | Shiseido Co Ltd | 毛質の評価方法 |
US8871518B2 (en) * | 2009-05-07 | 2014-10-28 | Otsuka Pharmaceutical Co., Ltd. | Monoclonal antibody for analyzing high-molecular weight adiponectin and utilization of same |
WO2010136896A1 (en) | 2009-05-29 | 2010-12-02 | Novartis Ag | Assays for influenza virus hemagglutinins |
CN101928348A (zh) * | 2010-02-01 | 2010-12-29 | 西安交通大学医学院第一附属医院 | 一种人tshr胞外段融合蛋白及其制备方法 |
PL2575872T3 (pl) * | 2010-06-01 | 2021-02-22 | Seqirus UK Limited | Zatężanie antygenów szczepionkowych grypy bez liofilizacji |
WO2012111249A1 (ja) * | 2011-02-14 | 2012-08-23 | 学校法人麻布獣医学園 | 質量分析法における質量変化を検出する方法及び安定同位体標識タンパク質の絶対量の定量方法 |
CN102586195B (zh) * | 2011-12-01 | 2013-09-04 | 哈药集团生物疫苗有限公司 | 一种利用Vero传代细胞制备禽流感病毒及其灭活疫苗的方法 |
CN103608453B (zh) | 2012-03-02 | 2018-07-24 | 思齐乐 | 流感病毒重配 |
JP2015519348A (ja) | 2012-05-23 | 2015-07-09 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | インフルエンザワクチン構築物 |
AU2014229255B2 (en) | 2013-03-13 | 2018-12-13 | Novartis Ag | Influenza B virus reassortment |
-
2016
- 2016-07-07 HU HUE16738395A patent/HUE051783T2/hu unknown
- 2016-07-07 CA CA2990745A patent/CA2990745A1/en active Pending
- 2016-07-07 WO PCT/EP2016/066200 patent/WO2017005880A1/en active Application Filing
- 2016-07-07 CN CN201680051676.0A patent/CN108027371B/zh active Active
- 2016-07-07 JP JP2017567171A patent/JP6830070B2/ja active Active
- 2016-07-07 CN CN202010717084.6A patent/CN111896742B/zh active Active
- 2016-07-07 HU HUE20193293A patent/HUE060924T2/hu unknown
- 2016-07-07 KR KR1020187003702A patent/KR102576962B1/ko active IP Right Grant
- 2016-07-07 EP EP16738395.9A patent/EP3320343B1/en active Active
- 2016-07-07 AU AU2016290603A patent/AU2016290603B2/en active Active
- 2016-07-07 BR BR112018000296-8A patent/BR112018000296A2/pt active Search and Examination
- 2016-07-07 EP EP20193293.6A patent/EP3764098B1/en active Active
- 2016-07-07 US US15/741,816 patent/US10416171B2/en active Active
- 2016-07-07 KR KR1020237030336A patent/KR20230132628A/ko not_active Application Discontinuation
-
2018
- 2018-10-18 HK HK18113418.7A patent/HK1254342A1/zh unknown
-
2019
- 2019-07-29 US US16/524,280 patent/US11249088B2/en active Active
-
2020
- 2020-11-26 JP JP2020196110A patent/JP7069281B2/ja active Active
-
2021
- 2021-12-29 JP JP2021215382A patent/JP7232893B2/ja active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021036909A5 (ja) | ||
Geiger et al. | Liquid–liquid phase separation underpins the formation of replication factories in rotaviruses | |
Steppert et al. | Purification of HIV-1 gag virus-like particles and separation of other extracellular particles | |
JP7298046B2 (ja) | インフルエンザヘマグルチニンタンパク質およびその方法 | |
Metz et al. | Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope | |
Srivastava et al. | Chemical proteomics tracks virus entry and uncovers NCAM1 as Zika virus receptor | |
Arora et al. | Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2 | |
Thompson et al. | Analytical technologies for influenza virus-like particle candidate vaccines: challenges and emerging approaches | |
Adungo et al. | Development and characterization of monoclonal antibodies to yellow fever virus and application in antigen detection and IgM capture enzyme-linked immunosorbent assay | |
US11273215B2 (en) | Synthetic polypeptide epitope based vaccine composition | |
Liu et al. | Development of a quantitative enzyme linked immunosorbent assay for monitoring the Enterovirus 71 vaccine manufacturing process | |
JP7232893B2 (ja) | インフルエンザ効力アッセイ | |
Manceur et al. | Critical review of current and emerging quantification methods for the development of influenza vaccine candidates | |
CN107827960A (zh) | Hpv的l1蛋白的定量检测方法 | |
Shytuhina et al. | Development and application of a reversed-phase high-performance liquid chromatographic method for quantitation and characterization of a Chikungunya virus-like particle vaccine | |
Santana et al. | Quantification of viral proteins of the avian H7 subtype of influenza virus: an isotope dilution mass spectrometry method applicable for producing more rapid vaccines in the case of an influenza pandemic | |
JP5914731B1 (ja) | 親水性相互作用クロマトグラフィー用充填剤、及び親水性化合物の分離方法 | |
Theillet et al. | Comparative study of chikungunya Virus-Like Particles and Pseudotyped-Particles used for serological detection of specific immunoglobulin M | |
Hickey et al. | Challenges and opportunities of using liquid chromatography and mass spectrometry methods to develop complex vaccine antigens as pharmaceutical dosage forms | |
US20120270255A1 (en) | Methods for isolating and quantifying antigen from vaccines | |
Fontes et al. | Precipitation of bovine rotavirus by polyethylen glycol (PEG) and its application to produce polyclonal and monoclonal antibodies | |
Kilbourne et al. | Hemagglutinin polymorphism as the basis for low-and high-yield phenotypes of swine influenza virus. | |
Ro et al. | Precolumn diastereomerization and micellar electrokinetic chromatography on a plastic microchip: Rapid chiral analysis of amino acids | |
Rabelo et al. | The effect of the dengue non-structural 1 protein expression over the HepG2 cell proteins in a proteomic approach | |
TWI419699B (zh) | 薔薇紅景天水性萃取物用於抗流感病毒及免疫調節的用途 |